T&J Brothers Group Participates as an Investor in Armlogi Holding's Nasdaq Closing Bell Ceremony

Los Angeles, CA – May 14, 2024 – T&J Brothers Group, a private investment and real estate consultancy firm, proudly announces its participation as an investor in the recent Nasdaq Closing Bell Ceremony hosted by Armlogi Holding Corp (Nasdaq: BTOC) at the Nasdaq MarketSite in Times Square, New York City.

Armlogi Holding Corp, a leading U.S.-based warehousing and logistics service provider, offers a comprehensive suite of supply-chain solutions encompassing warehouse management and order fulfillment. This significant event, held on May 14, 2024, marked a milestone for Armlogi Holding as they celebrated their achievements and the ringing of the Nasdaq Closing Bell by Mr. Aidy Chou, Chief Executive Officer of Armlogi Holding.

Event Details:

Date: May 14, 2024
Location: Nasdaq MarketSite, Times Square, New York City
Occasion: Nasdaq Closing Bell Ceremony

Mr. Aidy Chou led the ceremony, symbolizing Armlogi Holding's commitment to excellence and innovation in the logistics and warehousing sector.

T&J Brothers Group was honored to be part of this celebration as an investor, reflecting the close collaboration and shared values between the two companies. As an investment firm dedicated to fostering long-term structural value and industrial innovation, T&J Brothers Group aligns with Armlogi Holding's vision of providing efficient and cutting-edge supply-chain solutions.

"We were delighted to join Armlogi Holding at this significant event," said Yang, Partner at T&J Brothers Group. "Our participation underscores the strong partnership between our organizations and our mutual commitment to driving sustainable growth and innovation in our respective fields."

About T&J Brothers Group

T&J Brothers Group is a private investment and real estate consultancy firm. The company focuses on long-term value investing and industrial innovation across sectors such as biopharmaceuticals, hard technology, and real estate. T&J Brothers Group prioritizes sustainability, diversity, and ethical business practices.

About Armlogi Holding Corp

Armlogi Holding Corp (Nasdaq: BTOC) is a U.S.-based company specializing in warehousing and logistics services. It provides a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment. The company is dedicated to delivering efficient, reliable, and innovative logistics solutions to its clients.

Website: www.armlogi.com

For more details on the event, please visit the official Nasdaq page.

https://www.nasdaq.com/events/armlogi-holding-corp-rings-the-closing-bell

Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft

JUPITER, FL - (NewMediaWire) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft(R) will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20oC-25oC allowing it to be stocked directly on shelves in the Operating Room instead of the hospital pharmacy.

The change to the labeled storage temperature for US marketed product, cleared by the FDA through a 510(k) premarket notification pathway, presents significant advantages; the primary being that DuraGraft no longer requires storage in hospital pharmacy refrigerators. Pharmacy products are not readily available to the surgeon and must be ordered prior to surgery, presenting not only an inconvenience to the surgeon but also an additional step that may cause delays in initiating time-critical surgical procedures. For these reasons, a surgeon may not always opt to use DuraGraft. By making DuraGraft readily available in the operating suite, it can more easily and quickly be integrated into surgical procedures thereby driving adoption and increasing utilization.

Controlled room temperature storage of product also provides substantial logistics and cost saving advantages related to product warehousing and distribution as the product no longer requires cold warehouse storage and shipping, providing significant cost savings that are passed off to distributors and end users. Additionally, product can now be sold directly through hospital procurement channels as opposed to the more challenging hospital pharmacy pathway.

"We believe this FDA 510(k) clearance provides substantial advantages to the surgeon, patient and supply chain of the product and supports our commitment to improving patient outcomes in cardiac surgery," said David Barthel, CEO of Marizyme, Inc.

About DuraGraft

DuraGraft is the first and only FDA authorized product intended for flushing and storage of the saphenous vein grafts from harvesting through grafting for up to 4 hours in adult patients undergoing Coronary Artery Bypass Grafting (CABG), surgeries. The labelled mechanism of action is the reduction of oxidative damage to maintain the structural and functional integrity of vascular conduits.CABG is the most common type of open-heart surgery in the United States with more than 500,000 surgeries performed each year.

About Marizyme

Marizyme, Inc. is a medical technology company changing the landscape of cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Marizyme's first in-class product, DuraGraft, was granted a De Novo on October 4, 2023, from the U.S. Food and Drug Administration (FDA). With its CE Mark, DuraGraft continues to drive sales growth internationally in Europe and Asia and will now target the U.S. market to further drive utilization and sales.

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

Published: Apr 16, 2024

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. 

DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA).  DuraGraft™ is labeled for use as a vascular conduit solution indicated for adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries and is intended for the flushing and storage of the saphenous vein grafts used in CABG surgery. According to the Society of Thoracic Surgeons, there are over 500,000 CABG procedures performed annually in the U.S., representing a major market for this commercial-ready product.  

Pursuant to the Agreement, Qualigen will help support the commercial launch in the United States of DuraGraft™, including post-clearance clinical studies to advance the use of DuraGraft™ in the U.S., by providing up to $1.5 million in funding over the next several months for these purposes.  In return, Qualigen will receive a share of Marizyme’s gross profit on future U.S. sales of the product, capped at a 2X return on Qualigen’s invested capital. Qualigen has also purchased an exclusive negotiation period ending May 31, 2024, for purposes of proposing and outlining a broader strategic relationship between the two companies.

David Barthel, CEO of Marizyme, stated: “This is an exciting opportunity for Marizyme to accelerate the commercialization of DuraGraft™.  In addition to the non-dilutive funding that Qualigen will provide, we believe strongly in the importance of this technology and commercial potential for DuraGraft™ in the United States, and look forward to building this strategic relationship.”

Michael Poirier, CEO of Qualigen, stated: “We are thrilled to be supporting the Marizyme team.  This agreement provides Qualigen with participation in an FDA-cleared commercialization project with a visible path to revenue generation in the short term.  It also allows us the flexibility to broaden this relationship over the next four months.” 

About Marizyme

Marizyme, Inc. is a medical technology company changing the landscape of cardiac care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery. Marizyme's first in-class product, DuraGraft™, was granted a de novo clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™, with its CE Mark, continues to drive sales growth for Marizyme internationally in Europe and Asia, and will now target the U.S. market to drive further utilization and sales.

For more information about Marizyme, please visit www.marizyme.com.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Until the sale of its diagnostic business in 2023, Qualigen had a 20+ year history developing, marketing and selling medical devices in the United States and internationally. Currently, Qualigen’s investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. QN-302 is currently in a Phase 1a clinical trial.  The preclinical compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.  

For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com .

Forward-Looking Statements

This news release contains forward-looking statements by Marizyme and Qualigen Therapeutics (the “Companies”) that involve risks and uncertainties and reflect the Companies’ judgment as of the date of this release. These statements include those related to the Companies’ prospects and strategy for development of the Companies’ medical devices and therapeutic drug candidates. Actual events or results may differ materially from the Companies’ expectations. The Companies’ stock prices could be harmed if any of the events or trends contemplated by the forward-looking statements fail to occur or is delayed or if any actual future event otherwise differs from expectations. Potential risks include, not are not limited to, the failure of Marizyme to fully commercialize its products, failure to properly price or market the products in the United States, the need for additional funding to complete studies, manufacturing and other important tasks to sell the products, safety concerns with the use of the product, regulatory delays, and other similar risks. Additional information concerning these and other risk factors affecting each of the Company's business can be found in the respective Company's prior filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, all of which are available at www.sec.gov. 

The Companies disclaim any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Marizyme CEO Delivers Business Update

October 23, 2023

JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel:

“I am very pleased to bring you an update on the Company’s FDA Clearance for DuraGraft™ as well as Marizyme’s business priorities for 2024.

“After our last business update on May 3, 2023, the Company has been focused on securing FDA clearance for DuraGraft, developing our United States (U.S.) commercialization plan, completing our application for new technology add-on payments (NTAP) designation for Medicare reimbursement for DuraGraft™ (beginning in October 2024), and driving DuraGraft revenue in Europe and Asia. We have been successful or made progress in all these strategic initiatives.

“The big news and win is that we were granted a De Novo – FDA Clearance – on October 4, 2023 from the U.S. Food and Drug Administration (FDA) for our first-in-class product, DuraGraft™. DuraGraft is labelled for use as a vascular conduit solution indicated for adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries and is intended for the flushing and storage of the saphenous vein grafts used in CABG surgery. This is a huge accomplishment for the Company and will allow us the opportunity to market DuraGraft in the U.S. for the 500,000 CABG procedures performed annually in the U.S.1

“Our U.S. commercialization plan is focused on penetrating and driving utilization in hospital integrated networks and the cardiac suite, utilizing a small targeted and efficient direct sales force, direct sales targeting with patient focus on diabetics, and high-risk patients and utilizing digital marketing. We are excited with the opportunity to drive immediate revenue based on our strong clinical data and indication for use.

“We have also had success this year driving DuraGraft™ sales in Europe and Asia, with 1,131 DuraGraft™ kits shipped so far this year, compared to the 485 DuraGraft™ kits shipped last year. We have been working closely with our new distribution partners in Austria, the UK and Italy. We are anticipating continued sales growth in 2024.

“We have also been raising capital and reducing expenses where possible. We believe that our focus on aligning resources with business priorities continues to show results.

“As part of our U.S. commercialization plan, we have been working with a large hospital integrated network to execute on a strategic partnership for a planned multi-center randomized DuraGraft™ clinical trial in the U.S. and a utilization agreement to use DuraGraft™ across the hospital network.

“Additionally, the Company continues to expand its intellectual property (IP) position for DuraGraft™ in the U.S. and around the globe. Here are our 2024 business priorities:

2024 Business Priorities

• DuraGraft™ U.S. commercialization including engagement of hospital integrated networks and utilization with a small direct sales force.

• Pursuing potential strategic partnership for a multi-center DuraGraft™ clinical trial and utilization agreement.

• Increasing European Union sales with our exclusive distribution partners.

• Manufacturing sustainability with U.S. manufacturing and logistics providers.

• Executing our business plan with our cardiac care focus.

• Expanding the DuraGraft™ product platform with a powder formulation.

• Establishing strengthened capital resources and maintaining corporate governance.

• Developing further our intellectual property portfolio.

• Supporting publications and clinical data on DuraGraft™ to support commercialization.

Final Thoughts

"I will continue to provide further updates on our business developments and plans in the months to come. It has been a long road for everyone, but as we approach 2024, we have built this business with strong fundamentals, a talented team and a very lean and efficient operation. I look forward to a very successful 2024.

“I want to thank everyone involved in Marizyme for their support and commitment to the Company. Please feel free to reach out to me with any questions at DBarthel@marizyme.com.”

About Marizyme

Marizyme, Inc. (OTCQB:MRZM), Jupiter, FL is a medical technology company dedicated to the accelerated development and commercialization of innovative products that improve patient outcomes. Marizyme’s flagship product, DuraGraft™, has been granted a de novo from the U.S. Food and Drug Administration, allowing the Company to focus on changing the landscape of cardiac care by delivering innovative solutions for Coronary Artery Bypass Grafting surgery. DuraGraft™, with its CE Mark, continues to drive sales growth for the Company internationally and will now target the U.S. market to drive utilization and sales.

For more information about Marizyme, please visit www.marizyme.com.

Forward Looking Statements

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense.  Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.  Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control, including the risks described in the Company annual reports on Form 10-K under the heading “Risk Factors” as filed with the SEC.  Actual results and financial condition may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Forward-looking statements in this press release speak only as of the date hereof.  Unless otherwise required by law, the Company undertakes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:
Harrison Ross, Marizyme, Inc.
561-433-6626
Hross@marizyme.com

1 The Society of Thoracic Surgeons, “Coronary Artery Bypass Grafting (CABG).” The Patient Guide to Heart, Lung, and Esophageal Surgery, May 2019.

Source: Marizyme Inc.

Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™

DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries

JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its first in-class product, DuraGraft™. DuraGraft is labelled for use as a vascular conduit solution indicated for adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries and is intended for the flushing and storage of the saphenous vein grafts used in CABG surgery.  The mechanism of action for DuraGraft is through the reduction of oxidative damage which maintains the structural and functional integrity of vascular conduits. DuraGraft has been studied extensively in clinical studies including imaging studies.  These studies show that saphenous vein grafts treated with DuraGraft have reduced graft wall thickening compared to standard-of-care, saline treated grafts at 12 months post-CABG surgery.  DuraGraft use is also associated with reduced long-term mortality through three years post-CABG surgery.

Cardiac care is a large and rapidly growing industry; according to the CDC the estimated average annual US cost of coronary heart disease is $219 billion.  CABG is the most common type of open-heart surgery in the United States with more than 500,000 surgeries performed each year.  David Barthel, Marizyme CEO, stated that DuraGraft has the potential to change the landscape of cardiac care.

With the granting of this de novo, DuraGraft is the first and only medical product that is FDA cleared for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries and is also the only approved product available for this indication in Europe and other countries.

DuraGraft is the only patented product for this indication in CABG and other vascular surgeries.  The DuraGraft patent portfolio is growing and includes granted patents and pending applications in over 30 countries throughout the world, including patents granted in the United States, Europe, Australia, India, Argentina, South Africa, Mexico, and several Asian countries.

With the FDA de novo granted, the Company will now focus on executing its plan for US commercialization with an emphasis on driving utilization in hospital integrated networks using its own direct sales force.

“With this significant milestone reached, our company, Marizyme, can now present this breakthrough to cardiac surgeons and their CABG patients.  This is a rapidly growing market that provides Marizyme the opportunity to meet its mission statement and completely change the landscape of cardiac care.” - David Barthel, CEO, Marizyme, Inc.
  
About Marizyme:
Marizyme is a global medical technology company focused on the development of products to address unmet clinical needs.  Marizyme has a diverse pipeline portfolio and is currently focused on the development and commercialization of medical technologies in cardiac care, mainly through its flagship product, DuraGraft.

DuraGraft™ is cleared for use in the US and approved for use in the EU and certain other markets.  For more information about Marizyme, please visit www.marizyme.com.

Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products

May 10, 2023 08:00 ET| Source: Marizyme Inc.

JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies that improve patient health outcomes, announced today that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.

Patents have recently been granted in the United States, India, South Korea, and Vietnam covering the Company’s flagship commercial product, DuraGraft™, and patent applications have additionally been allowed in Canada and Vietnam. The issued patents and allowed patent applications protect Marizyme’s flagship commercial product DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States. It is considered an investigational product in the United States and is not yet authorized for use in the United States.

“The countries in which patents are allowed or granted represent large and rapidly expanding cardiac surgery markets and significantly expand our patent estate for DuraGraft and present tremendous commercialization and licensing opportunities for us,” said David Barthel, Marizyme’s CEO.

The DuraGraft patent portfolio now includes granted patents and pending applications in over 30 countries throughout the world, including patents granted in the United States, Europe, Australia, India, Argentina, South Africa, Mexico, and several Asian countries, and pending related applications in the U.S. and other countries.

Another patent application covering Marizyme’s Krillase™ enzyme technology was recently allowed in Europe resulting in additional patent protection. The patent relates to mixtures of enzymes from Antarctic krill for use in the treatment of a disease related to, or an inflammatory condition caused by, a biofilm formed on a soft tissue of a mammal with the treatment including treating soft tissue with Krillase to remove or prevent formation of a biofilm.  Krillase products are currently under development and not yet authorized for use.

Additionally, a patent application covering Marizyme’s MATLOC™ technology was also recently allowed in Europe.  The patent application relates to a method for mixing two reagents to produce a detectable reaction in a microfluidic chip.  The method allows for the detection of albumin and/or creatinine using a passive mixing microfluidic chip to be potentially used for chronic kidney disease assessment.  MATLOC devices are currently under development and not yet authorized for use.

Marizyme’s global patent and IP portfolio is managed by Dentons US LLP, the world’s largest law firm with hundreds of patent lawyers and IP professionals in more than 80 countries.  Dentons US LLP provides quality seamless legal services on an international scale.  Dentons has been consistently ranked for the past years as a top leading life sciences and health care law firm.  “Joining forces with Dentons has allowed Marizyme to step up innovation, growth and value creation in markets around the world, which is important as we continue to expand and protect our intellectual property,” said David Barthel.

About Marizyme:

Marizyme is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes. Marizyme is focused on the development and commercialization of medical technologies, devices and related products. Currently, we are focused on developing three medical technologies and products – DuraGraft™, MATLOC™ and Krillase™ – each of which is backed by a portfolio of patented or patent-pending assets.

DuraGraft® is approved for use in the EU as well as certain other markets. DuraGraft™ has not been approved for use in the U.S. MAR-FG-001, MATLOC™ and Krillase™ are not approved for sales in any market.  For more information about Marizyme, please visit www.marizyme.com.

For information relating to the IP of Marizyme, Inc. please contact info@marizyme.com or 914-714-8615.

Forward Looking Statements

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense.  Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.  Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control, including the risks described in the Company annual reports on Form 10-K under the heading “Risk Factors” as filed with the SEC.  Actual results and financial condition may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Forward-looking statements in this press release speak only as of the date hereof.  Unless otherwise required by law, the Company undertakes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:
Harrison Ross, Marizyme, Inc.
561-433-6626
Hross@marizyme.com

T&J Brothers group discloses its recent progress.

Los Angeles, CA, 8/7/2023 – T&J Brothers Group, LLC, a privately held investment company and real estate consultancy firm with a strong commitment to social responsibility, proudly announces a significant milestone within its portfolio. Marizyme, Inc., a company in which T&J Brothers Group invested three years ago, has filed an S1 for uplisting to senior exchange such as Nasdaq or the NYSE in July 2023, and being listed as one of its principal stockholders (1). T&J Brothers Group is excited to witness Marizyme’s progress and looks forward to the potential growth and positive impact of this development in the healthcare innovation sector.

Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies that improve patient health outcomes, announced today that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.

Marizyme’s flagship product, DuraGraft®, and the company has granted patents covering this product in the United States, India, South Korea, and Vietnam. The issued patents and allowed patent applications protect Marizyme’s flagship commercial product DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.

(DuraGraft®, is an investigational product used during Coronary Artery Bypass Grafting (CABG) surgery.)

Building on their international success, Marizyme is looking to enter the US market. Yet, DuraGraft is currently under review by the FDA for authorization in the United States.

“The countries in which patents are allowed or granted represent large and rapidly expanding cardiac surgery markets and significantly expand our patent estate for DuraGraft and present tremendous commercialization and licensing opportunities for us,” said David Barthel, Marizyme’s CEO.

T&J Brothers group has beliefs in making a meaningful impact on society and the environment centers around responsible and sustainable practices, prioritizing the well-being of current and future generations. Marizyme inc has being one of their key investments.

They are convinced that healthcare innovation for coronary artery disease treatments offers significant benefits by delivering better and accessible medical solutions, improving patient outcomes, and potentially alleviating the strain on healthcare systems through more effective prevention and management of this common cardiovascular condition.

About T&J Brothers group:

T&J Brothers Group is an California llc, founded by zhonghao chen and xingyu yang, the company is a private investment company and real estate consultancy firm. With an active pursuit of both private and public investment opportunities worldwide, the company focuses on long-term structural value investing and industrial innovation across sectors like biopharmaceuticals, life health, and hard technology. Its investment portfolio encompasses early-stage venture capital, public companies, and merger and acquisition deals. Alongside offering business consulting for small enterprises and consultancy services for small-scale real estate investments, T&J Brothers Group remains committed to Environmental, Social, and Governance (ESG) principles. They prioritize sustainability, reduce their carbon footprint, preserve biodiversity, and embrace renewable energy. The company promotes diversity and inclusion in the workplace, engages with local communities for social development, and upholds ethical practices with transparency through a diverse and independent board.

Source:

1: SEC: Marizyme S1 filing(Pg. 126) : https://d18rn0p25nwr6d.cloudfront.net/CIK-0001413754/14bcff86-f30f-4a3a-9848-908e7f7ec436.pdf

www.tjbrothers.com/about-us

www.globenewswire.com/news-release/2023/05/10/2665486/0/en/Marizyme-Announces-IP-Developments-for-DuraGraft-and-Its-Pipeline-Products.html

medcitynews.com/?sponsored_content=new-technology-for-cabg-surgery-procedures

New Technology for CABG Surgery Procedures

Medical Technology company Marizyme, Inc. highlights its flagship product, DuraGraft®.

Jun 15, 2023 at 12:00 PM

Marizyme, Inc. (OTCQB:MRZM) is a medical technology company dedicated to the accelerated development and commercialization of devices that improve patient outcomes. This MedTech company has achieved several milestones and looks to complete many more in 2023.

Marizyme’s flagship product, DuraGraft®, continues to make impressive strides in the cardiac surgery industry and is generating revenue internationally in countries including Spain, the Philippines, Germany, Switzerland, Singapore, Malaysia, Turkey, Ireland, Austria, and the UK. Building on their international success, Marizyme is now looking to enter the US market. According to a business update provided by the Company on May 5, 2023, DuraGraft is currently under review by the FDA for authorization in the United States.

The Company also continues to strengthen the IP around DuraGraft®, with patents recently granted in the United States, India, South Korea, and Vietnam. Additional patent applications have been allowed in Canada and Vietnam. For more information on DuraGraft’s IP, and Marizyme’s other related technologies, please refer to their latest news release:
Marizyme Announces IP Developments for DuraGraft and Its Pipeline Products

Current Landscape of CABG Surgery

Coronary Artery Bypass Graft (CABG) surgery is the most common cardiac surgery in the world with over 1 million CABG procedures performed annually worldwide.(1) With an estimated 500,000 procedures performed annually in the US alone, expansion into the US market is essential, and Marizyme is well positioned to take a piece of the ~$16.1 billion market.(2)(3)

During CABG surgery, bypass grafts are used to re-route blood around blockages in native coronary arteries. The types of grafts used are most often the patient’s own vessels. It is important to remember that the new graft (vein/artery) is alive and fragile. It deserves the same protection and treatment as any other tissue or organ being transplanted.

DuraGraft® is a first-in-class CE marked intra-operative graft storage and flushing solution used during coronary artery bypass graft surgeries. DuraGraft is authorized for use in Europe and other counties outside of the United States, DuraGraft is not yet authorized for use in the United States.

Pipeline Products

Marizyme seeks to be an innovator to address unmet clinical needs in plastic and reconstructive surgery — specifically fat grafting. Fat grafting is a surgical process used in medical reconstructive and other plastic surgery procedures in which fat is transferred from one area of the body to another (known as “autologous fat grafting” or simply “fat grafting”) to correct a defect, replace injured tissue, or to make cosmetic enhancements. MAR-FG-001 is formulated as a tumescent solution base that protects adipose tissue during adipose tissue harvesting and storage.
The global market for autologous fat grafting was estimated to be $699.96 million in 2021 and is projected to grow at a CAGR of 8.62% until 2028 (“Global Autologous Fat Grafting Market – Industry Trends and Forecast to 2028,” Data Bridge Market Research December 2020).

According to Data Bridge Market Research, the global market for autologous fat grafting was estimated to be $699.96 million in 2021 and is projected to grow at a CAGR of 8.62% until 2028. With 22.4 million plastic surgeries performed annually in the United States(4) there is potential for widespread implementation of innovative fat grafting systems.

MATLOC™, a second pipeline product currently under development has been designed for the screening and diagnosing of chronic kidney disease (CKD) at point-of-care. In the US, about 37 million people have CKD and approximately 80 million people are at risk for developing it. But the majority (90%) who have this chronic condition are not even aware of it, according to the CDC. MATLOC will increase testing, early detection, and continuous monitoring of CKD and its progression to facilitate timely therapeutic and clinical intervention at an early disease stage when interventions can be effective in slowing disease progression.

In conclusion, Marizyme is a medical technology company with a strong focus on the commercialization of its flagship product, DuraGraft, supported by the development of its pipeline products. Marizyme provides a well-rounded opportunity – investors and medical professionals alike would be wise to keep a close eye on Marizyme’s progress and its potential impact on the global healthcare landscape.

To learn more about Marizyme, Inc., please visit their website at: click here.

[1] Weill Cornell Medicine. (2020, July 7). Method using artery for coronary artery bypass linked to better long-term outcomes than vein grafts. Weill Cornell Medicine Newsroom. https://news.weill.cornell.edu/news/2020/07/method-using-artery-for-coronary-artery-bypass-linked-to-better-long-term-outcomes-than
[2] HonorHealth. (n.d.). Coronary artery bypass grafting. HonorHealth. https://www.honorhealth.com/medical-services/cardiac-care/treatment-options/coronary-artery-bypass-grafting
[3] Mordor Intelligence. (2021). Coronary Artery Bypass Grafting Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026). Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/coronary-artery-bypass-grafting-market
[4] American Society of Plastic Surgeons. (2020). Plastic Surgery Statistics Report. American Society of Plastic Surgeons.
https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf

T&J Brothers Group partner, Zhonghao Chen accepted into Forbes Business Council

Forbes Business Council is an invitation-only community for successful business owners and

Leaders.

Los Angeles, CA, August 3, 2023, T&J Brothers Group LLC, a private investment and consulting company, announces that their associate has been welcomed as a member of the Forbes Business Council. This prestigious council is recognized as a leading global platform for accomplished business owners and leaders, offering opportunities for growth and networking.

Zhonghao's selection was made by a review committee, which considered his extensive and diverse experience. The acceptance criteria were centered around a proven track record of effectively contributing to business growth metrics, along with recognition of personal and professional accomplishments and accolades.

 Zhonghao: I am elated to be a part of the Forbes Business Council, as it offers a fantastic opportunity to share my expertise and connect with fellow professionals in my industry. This esteemed platform provides a powerful avenue for collaboration and learning from accomplished individuals, driving our company towards greater success. The chance to engage with industry leaders and exchange innovative ideas is truly invigorating. The Forbes Business Council's vast network and resources will undoubtedly enhance our strategic vision, enabling us to expand and thrive on a higher scale. I look forward to contributing actively, fostering meaningful relationships, and embracing the exciting prospects that lie ahead.

 About T&J BROTHERS GROUP

 T&J Brothers Group is a private investment and real estate consultation company with significant capital from a multi-family office and strong connections in real estate, wealth, and financial services. They actively pursue global private and public investment opportunities, focusing on long-term value investing and industrial innovation in areas like biopharmaceuticals, technology, and carbon neutrality. Their diverse investments span early-stage venture capital, private equity, public companies, and M&A.

 ABOUT FORBES COUNCILS

 Forbes Councils is a collective of invitation-only communities created in partnership with

Forbes and the expert community builders who founded Young Entrepreneur Council

(YEC). In Forbes Councils, exceptional business owners and leaders come together

with the people and resources that can help them thrive.

SOURCE T&J Brothers Group

Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

Dec. 23, 2021 3:31 PM ET | Source: Marizyme Inc.

Jupiter, FL - (NewMediaWire) - December 23, 2021 - Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. (TSXV:CHIP.H), along with a concurrent financing.

My Health Logic’s “lab-on-chip” technology platform and patient-centric digital point-of-care device, MATLOC 1, further strengthens Marizyme’s life science technology product pipeline. Marizyme is actively seeking FDA approval for both MATLOC1 and a second product, DuraGraft.

My Health Logic’s MATLOC and Lab-on-Chip Technology Platform

The excitement over microfluidics, also known as lab-on-a-chip technology, lies in its potential for producing revolutionary, timely, accessible, and practical point-of-care devices; devices that are patient-centric (one-to-many, rather than doctor centric, one-to-one) and support self-care and independence. Microfluidics is a technology for analyzing small volumes of fluids, with the potential to miniaturize complex laboratory procedures onto a small microchip, hence the term “lab-on-chip” (LOC).

My Health Logic’s lab-on-chip technology is currently being developed to diagnose the three leading biomarkers for chronic kidney disease (CKD), a disease estimated to affect 37 million Americans – or one out of every seven people – and which costs the US public healthcare system over $80 billion a year. By combining the lab-on-chip technology with MATLOC 1 we expect to be able to quantitatively read the two urine biomarkers, albumin and creatine, necessary for effective CKD screening at point-of-care with results available instantly on a patient’s smartphone.

MATLOC 2, the Company’s next generation point-of-care device is designed to quantitatively assess eGFR using a blood-based biomarker. eGFR is a key measure of kidney function health and/or stage of kidney disease and is designed to provide a complete quantitative diagnostic assessment for CKD, potentially eliminating the need for lab visits and in-person assessment.

The COVID Pandemic massively accelerated the ongoing transformation in Healthcare. Connected consumer electronic devices are enabling 24/7 home-based digital healthcare. Consumers have the desire and are now empowered to manage their own healthcare.

With MATLOC we strive to create earlier detection and prevention of CKD, allowing patients and healthcare systems to prevent the enormous costs of kidney failure, transplant, and/or dialysis. After completing the technology for CKD assessment, the Company plans to explore other biomarkers for chronic diseases to be measured at point-of-care.

Acquisition of Senior Officers and New Appointments of CFO and VP of Finance

Additionally, Marizyme is pleased to announce that David Barthel, who was appointed as Marizyme’s Chief Executive Officer on November 10, 2021, was appointed as a member of the Company’s board of directors on December 20, 2021.

Also, two of My Health Logic’s senior officers, George Kovalyov, CPA, and Harrison Ross, CFA will join the Company in leadership roles.

George Kovalyov will become Marizyme’s CFO. Mr. Kovalyov is a founding member of the My Health Logic team and is a CPA with cross border transaction experience. Before My Health Logic, Mr. Kovalyov was VP of Finance for Phivida Holdings, a publicly traded Company that raised over $19 million post its IPO and was successfully acquired. Furthermore, Mr. Kovalyov has 11 years’ experience as a financial controller, working on public company audits and financial statements for both US GAAP and IFRS.

Harrison Ross will become Marizyme’s VP of Finance. Mr. Ross is another founding member of the My Health Logic team and brings extensive knowledge of the MATLOC device and the accompanying lab-on-chip technology. Mr. Ross has experience in both public and private capital markets. In addition to creating another currently TSXV-listed company, Mr. Ross spent 9 years on the buy-side managing investments at registered firms and family offices.

Marizyme Announces Financing

Marizyme is also announcing that, concurrent with the closing of the My Health Logic Acquisition, the Company closed a private placement in the amount of $6 million, consisting of Units of Convertible Notes and Warrants at a price per Unit of $1.75.  This new investment will allow the Company to continue with its business development needs and prepare and file with the Securities and Exchange Commission (the “SEC”) a Form S-1 registration statement (the “Registration Statement”) for an anticipated public offering and Nasdaq uplisting in 2022.  Subject to satisfaction of certain conditions, the purchaser of the Units has agreed to invest up to an additional $4 million in the Company. Specifically, the Purchaser has agreed to subscribe for $2,000,000 in additional Units upon the Company’s filing of the Registration Statement, and an additional $2,000,000 upon the Company’s submission of responses to a first round of comments on the S-1 filing expected to be received from the SEC shortly after the S-1 filing.  In connection with this investment, the company also exchanged approximately $1,456,039 in previously-issued outstanding convertible notes and warrants in exchange for the new Convertible Notes and Warrants.

About Marizyme, Inc.

Marizyme is a life science company, based in Jupiter, FL that is engaged in the research, development and commercialization of technologies and products to prevent, treat and diagnose diseases with unmet clinical needs. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure after bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.

About My Health Logic

My Health Logic is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient's smartphones and digital continued care platforms. The Company plans to use My Health Logic’s patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient's smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. More information about My Health Logic is available at www.healthlogicinteractive.com.